A single-center, real-world experience of atezolizumab plus bevacizumab as first-line therapy in patients with unresectable hepatocellular carcinoma, including patients with advanced cirrhosis.
| Autor: | Parekh, Jay, Abraham, Soniya, Andanamala, Haripriya, Rehman, Asad, Ahearn, Paul, Adjepong, Yaw, Buller, Gregory, Stein, Stacey |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p445-445, 151p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|